ASBMR Issues Statement/Comments on ICER Draft Evidence Report on Anabolic Therapies for Osteoporosis in Postmenopausal Women: Effectiveness and Value
Date: June 08, 2017
ASBMR has issued a statement to the media on the Institute for Clinical and Economic Review (ICER) Draft Evidence Report on “Anabolic Therapies for Osteoporosis in Postmenopausal Women: Effectiveness and Value.” This draft report assesses the comparative clinical effectiveness and value of three treatments for osteoporosis in postmenopausal women: abaloparatide (TymlosTM, Radius Health, Inc.), romosozumab (Amgen, Inc. and UCB, Inc.), and teriparatide (Forteo®, Eli Lilly and Co.). Abaloparatide was approved by the FDA last week and romosozumab is currently under FDA review.
ASBMR has actively engaged with ICER as a stakeholder through the development of this report, providing comments on the scoping document and on earlier drafts. . The ASBMR Professional Practice Committee (PPC) has also reviewed the report in detail and provided . PPC Chair Benjamin Leder, M.D. will be representing the ASBMR and providing public testimony on the report at a planned public meeting on June 30. ASBMR members have also been participating on the National Bone Health Alliance (NBHA) ICER work group to provide direct feedback on the report to ICER, co-chaired by Robert Adler (ASBMR) and Kenneth Saag (NOF). For more information about the process for public input on the report, click here to view the full ICER press release